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Oral Presentations 
and mortality in patients undergoing SCT. Risk factors for acqui- 
sition, progression to lower respiratory tract infection (LRI), and 
the effect of antiviral therapy are unknown. Methods: Virology 
records were reviewed for cases of FLU infection from day of 
transplant until 120 days after SCT over the last 12 FLU seasons. 
Results: From 9/1/89 until 3/31/02, FLU was isolated from 62 of 
4797 SCT recipients (1.3%); 44 were upper respiratory tract 
infections (URI) alone, while 18 developed LRI. In multivariate 
models that adjusted for FLU season, female gender and advanced 
underlying disease were associated with risk for FLU acquisition 
(Table). Among patients with FLU, LRI was more common 
among those with lymphocytes < 100 (Table) and earlier time of 
infection after transplant (median 36 days vs. 6i days, p=0.04). 
Interestingly, patients receiving steroids for graft vs. host disease 
at the time of diagnosis were less likely to develop LRI. Of the 51 
cases that were initially diagnosed as URI, 17 were treated with 
antivirals and 34 received no treatment; 6 (18%) of untreated 
patients developed LRI, while 1/8 (13 %) treated with rimantadine 
and 0/9 treated with neuraminidase inhibitors (NAI) developed 
LRI. FLU shedding was longer in patients treated with > 1 mg/kg 
steroids (mean 15 days vs. 9 days for those receiving < 1 mg/kg); 
NAI (but not rimantidine) decreased shedding after controlling for 
steroid use (P-0.08). FLU-associated eath (mortality within 30 
days of infection) occurred in 6/62 (9.7%); FLU-associated mor- 
tality in LRI cases was 28% (5/18). Multivariate analysis howed 
that FLU LRI was associated with 1-year mortality after adjusting 
for underlying disease, donor type, cell source, CNIV serostams, 
age at transplant, and year of SCT. Conclusions: FLU infection 
early after SCT is relatively uncommon; this *nay be due to an 
aggressive vaccination program. Overall, 29% of FLU infections 
developed lower tract involvement, which was more common ear- 
lier after transplant and in the presence of lymphocytopenia. 
While not a randomized trial (and sample size is small), our data 
suggests that early antiviral therapy (particularly with NAI) may 
prevent progression to pneumonia and decrease FLU shedding. 
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Delayed HCMV-specific immunereconstitution f llowing allo- 
geneic stem cell transplantation (allo SCT) leads to increased inci- 
dence of HCMV disease. In HCMV-seropositive patients under- 
going allo-SCT from a HCMV-seronegative donor it can take up 
to more than 18 months until HCMV-specific T-cell reconstitu- 
tion. Dendritic cells (DCs) have been used in several vaccination 
trials to induce antitumor immuni~ in patients with malignancies. 
Thns, in this phase I/II study DCs pulsed with HCMV pp65 
HLA-A2/A1 binding peptides were used to induce HCMV-specif- 
ic immune responses in 9 HCMV-seropositive patients receiving a
SCT from HCMV-seronegative/tmrelated donors. All patients 
were lacking HCMV-speciflc T-cell responses at time of DC-vac- 
cination and had a HCMV infection. Seven patients received > 4 
weeks of antiviral chemotherapy. None of the patients uffered 
frona HCMV disease at time of DC-vaecination. Reconstitution of
HCMV-specific hnmune-responses was assessed by intraccllular 
IFN-g or tetrameric-complexes staining. HCMV infection was 
documented by qPCR and antigenemia assay. Peptide-pulsed DCs 
were injected subcutaneously betv~een day 30 and day 60 post- 
transplant. The DC-vaccinations were well tolerated and none of 
the patients developed GvHD or autoilnmune phenomena follow- 
ing DC-vaccination. Apart from one patient who died due to 
recurrence of his underlying malignancy all patients are alive and 
well a median of 8 months post-vaccination. Complete data are 
available on 5 patients. In 4 of these an increase in the number of 
ltCMVpp65-specific T-cells was detected between 15 and 60 days 
post-vaccination. None of these 5 patients howed a reactivation 
of HCMV infection during a follow-up of > 6 months post-vacci- 
nation. In this study, we show for the first time that a vaccination 
with HCMV pp65-peptide pulsed donor-derived Des can be safe- 
ly applied after SCT. Comparative studies will have to show 
whether De-vaccination enhances HCMV-specific immunere- 
constitution post allografting. 
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Fiberoptic bronchoscopy with BAL is a clinically safe and usefol 
diagnostic procedure in HPCT pts and is often used with pul- 
monary complications post transplant. We retrospectively 
reviewed our experience with BAL as a diagnostic tool in one hun- 
dred thirty-nine consecutive patients who underwent HPCT at 
our institution. From January 1, 2000 to December 31, 2001, 39 
(28%) HPCT patients underwent a total of 62 BAL procedures. 
The median age was 48 years (range 22-64), 57% were male. 
Twenty-eight pts underwent an allogeneic HPCT and 9 pts had 
an autologous HPCT. Diseases which indicated HPCT included 
leukemia (n=18), NHL (n=10), MIM (n=7), other (n-2). BAL fluid 
was analyzed by rapid viral antigen assay (Chemicon Internation- 
al&#61650; ) for RSV, adenovirus, influenza, and parainfluenza; 
and cytology, gram stain, silver stain for PCP and fungms, AFB 
stain, PCR for CMV, and bacterial, fungal and viral cultures. Indi- 
cations for BAL were driven by radiographic findings of pul- 
monary infiltrates/nodules (74%) or respiratory s anptoms (26%). 
No post-HPCT patient had pre-existing lung disease. All BAL 
procedures were well tolerated with no reported complications. In 
32 (52%) of the BAL the following infections were identified: 
CMV (n=8), (4 by viral culture, 4 by PCR), Candida glabrata 
(n=7), bacterial infections (n=5), RSV (n=4), HHV6/HSV (n=5), 
fungal infections (n=2), and EBV (n=I). Thirty (48%) of the BAL 
procedures yielded no infectious pulmonary etiology. The final 
clinical diagnoses in this group included: idiopathic pneumonitis 
(n=10), diffuse pulmonary hemorrhage (n=6), bronchiolitis oblit- 
erans (n=5), recurrent malignancy (n=l), and no diagnoses (n=8). 
The diagnostic yield of the BAL for identifying a specific infec- 
tious pulmonary process was 52%. We conclude that BAL is a safe 
and useful diagnostic tool in HPCT patients with puhnonary 
complications. 
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Puhnonary disease is a frequent cause of morbidity and mortality 
following allogeneic HSCT. After observing several patients who 
developed ifficulty with PH associated with non-infectious inter- 
stitial pneumonitis, we conducted a retrospective r view of the 
incidence and effects of puhnonary hypertension i all patients 
who underwent allogeneic HSCT at our center between January 
1994 and September 2002 (N=103). All echocardiograms, autop- 
sies (N=23) and lung biopsies (N=31) done in these 103 patients 
were evaluated. ECHO's were routinely done pre-HSCT, at 3, 6, 
12 and 24 months post HSCT, and when cardiopulmonary prob- 
lems occurred. PH was diagnosed when ECHO showed R ven- 
tricular pressure>40mm Hg, R ventricular dilation, and/or R ven- 
,tricular hypertrophy. Histologic diagnosis of PH on autopsy or 
lung biopsy required finding intimal nmscle proliferation in pul- 
monary arterioles. PH was detected post-HSCT in 20 of 103 
patients (19%). Diagnosis was by ECHO in 16 cases, autopsy in 2 
and lung biopsy in 2. Median age at HSCT in PH patients was 8y 
(range, 6m-24y). PH was first recognized at a median of 62 days 
post-HSCT (range, day 0 to +631). The HSCT indication in 
patients with PH was ALL (N=9), AML (4), CML (2), NHL (2), 
